Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,810 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 29, 2026, 8:14 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus

NCT00228891
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Effect of Pulsatile IV Insulin on diabetic neuropathy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Not applicable Interventional Results available

Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm

NCT06728059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET+ BPS_RL→AIDANET
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Not applicable Interventional Results available

Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study

NCT02877680
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
T1Doing Well
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 1 Interventional

A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT03367390
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Full Day and Night Closed-Loop With DiAs Platform

NCT02147860
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Insulet Artificial Pancreas Free-Living IDE3

NCT03216460
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Insulet automated glucose control system
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
2 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Palo Alto, California • Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Diabetes Adolescent and Family Group Therapy

NCT01626586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Group Therapy
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

NCT02430870
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TAK-648, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Anaheim, California • Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

NCT00313183
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Aurora, Colorado • Kansas City, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

NCT03341013
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MEDI0382 Formulation 2, MEDI0382 Formulation 3
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

NCT03514420
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
AKCEA-ANGPTL3-LRx
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

ADJUnct Semaglutide Treatment in Type 1 Diabetes

NCT05537233
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • West Des Moines, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Exercise Activity-Based Bolus Decisions in Type 1 Diabetes

NCT03394352
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Activity on Board, Usual Diabetes Care
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 29, 2026, 8:14 AM EDT
Recruiting No phase listed Observational

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

NCT07155252
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
GTT@Home
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
8 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 29, 2026, 8:14 AM EDT
Recruiting Phase 2 Interventional

Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial

NCT06981234
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 29, 2026, 8:14 AM EDT
Enrolling by invitation Not applicable Interventional

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT06834204
View directory record Official record
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 29, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

NCT00143247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exubera® (inhaled insulin)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
12
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

NCT00372814
View directory record Official record
Conditions
Diabetes Mellitus, Insulin Dependent
Interventions
Intensive Home-Based Family Therapy, Supportive Telephone Calls
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

NCT00134147
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2008 · Synced Oct 29, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

Soy Protein in Early Diabetic Nephropathy

NCT00067678
View directory record Official record
Conditions
Diabetic Nephropathy, Diabetes Mellitus
Interventions
soy protein
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 29, 2026, 8:14 AM EDT